U.S. Stock Futures Steady Amid Bank Earnings and Inflation Focus 
Bank of America Signals End to Fed Rate Cuts Amid Robust Job Market 
Ex-CDC Director Says ‘Vaccine Makers Lied’ About COVID as He Urges Congress to End Liability Shield 
Apple Opposes Shareholder Proposal to End DEI Programs 
Gen Z are embracing mobile wallets according to Interac survey 
Texas Judge Rules American Airlines Breached Duty in Retirement Plan Investments 
China in Crisis as Viral Outbreak 'Overwhelms' Hospitals and Crematoriums Nationwide: Reports 
Will we have a COVID wave, spike or blip this Christmas? It depends where you live 
Bill Gates’ Shocking New Malaria Solution Unveiled as Genetically Modified Mosquitoes Turn Into Flying Vaccinators 
Sport produces mountains of high-tech waste. We are finding new ways to recycle it 
Energy Sector Outlook 2025: AI's Role and Market Dynamics 
Mandatory Masks in Health Care Sparks Outrage as New York, New Jersey, and California Enforce Winter Rules 
Microsoft Shareholders Reject Bitcoin Proposal, Sparking Debate on Crypto Investments 
From Cleopatra to Wellington, leaders have always taxed beer. But Australia’s system has made beer extra pricey 
Biden Administration Pauses Enforcement of Nippon Steel’s Bid for U.S. Steel 
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
